INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 141 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2016. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,676,109 | +53.9% | 82,875 | +55.5% | 1.36% | +51.7% |
| Q1 2024 | $3,687,322 | -2.6% | 53,285 | +0.8% | 0.90% | +0.7% |
| Q4 2023 | $3,787,624 | -46.9% | 52,885 | -53.1% | 0.89% | -9.7% |
| Q2 2023 | $7,132,998 | +107.4% | 112,650 | +77.4% | 0.99% | +106.0% |
| Q1 2023 | $3,439,067 | -43.3% | 63,510 | -44.5% | 0.48% | -42.0% |
| Q4 2022 | $6,061,139 | +54.0% | 114,534 | +35.4% | 0.83% | +57.4% |
| Q3 2022 | $3,936,000 | -79.0% | 84,584 | -74.2% | 0.53% | -79.3% |
| Q2 2022 | $18,716,000 | +9.9% | 327,894 | +17.8% | 2.54% | +32.9% |
| Q1 2022 | $17,035,000 | +3478.8% | 278,395 | +2170.8% | 1.91% | +166.4% |
| Q2 2016 | $476,000 | – | 12,260 | – | 0.72% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |